Please assess the completion status of the following clinical trial:

Trial Title: B Cell Response to a Primary and a Booster Course of the Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Infants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~Subjects who were eligible to be enrolled in the study:~* healthy infants aged 2 months (56 - 83 days old, inclusive);~* available for the visits scheduled in the study;~* mother available for blood draw at Visit 1;~* good health as determined by the clinical judgement of the investigator;~* whose parents gave written informed consent for the infant to be enrolled in the study. The infant's parents must have been willing for the infant to receive the full primary immunization course.~Exclusion Criteria:~Subjects who were not eligible for the study were those:~* whose parents had not given or were unwilling or unable to give written informed consent to their child's participation in the study~* with known hypersensitivity to any vaccines contained within the routine immunization schedule~* with unacceptable concurrent illnesses or conditions - e.g.:~  1. a severe acute or chronic illness; with any present or suspected serious disease such as metabolic, cardiac or autoimmune disease or insulin dependent diabetes or with any other serious disease (e.g., with signs of cardiac or renal failure or severe malnutrition), including progressive neurological disease;~ 2. a genetic anomaly, e.g. Down's syndrome;~ 3. any immunodeficiency, including use of systemic corticosteroids;~ 4. born at less than 36 weeks gestation;~ 5. weighing less than 2.5 kg at birth;~ 6. previous clinical or bacteriological diagnosis of meningitis, or with a history of household contact or intimate exposure to an individual with culture proven Neisseria meningitidis disease;~ 7. known bleeding diathesis, or any condition associated with a prolonged bleeding time;~* who have received any prohibited prior or concomitant medications - e.g.:~  1. any immunizations within the 30 days prior to enrollment, with the exception of BCG or hepatitis B;~ 2. immunoglobulin;~ 3. any blood products;~* participating in any other clinical trial either currently or in the previous month;~* unable to adhere to the protocol, including plans to move from the area;~* Other:~Had any condition which, in the opinion of the investigator, might interfere with the evaluation of the study objectives.

- Gender: ALL
- Minimum Age: 56 Days
- Maximum Age: 83 Days
- Healthy Volunteers: t

Study Arms:
- MenACWY-CRM and Routine Vaccines (Group 1) (Type: EXPERIMENTAL): Infants received 2 doses of MenACWY-CRM (at 2 and 4 months) as a primary course of vaccination and third dose (at 12 months) as a booster. Infants also received routine vaccines - 3 doses of DTaP-Hib-IPV (at 2, 3, and 4 months), 3 doses of PCV (at 2, 4, and 13 months), and 1 dose each of MMR and Hib (booster) at 13 months.
- MenACWY-CRM and Routine Vaccines (Group 2) (Type: EXPERIMENTAL): Infants received 2 doses of MenACWY-CRM (at 2 and 4 months) as a primary course of vaccination and third dose (at 12 months) as a booster. Infants also received routine vaccines - 3 doses of DTaP-Hib-IPV (at 2, 3, and 4 months), 3 doses of PCV (at 2, 4, and 12 months), and 1 dose each of MMR and Hib (booster) at 13 months.~This group had an additional blood draw at the time of enrollment.
- MenACWY-CRM and Routine Vaccines (Group 3) (Type: EXPERIMENTAL): Infants received 2 doses of MenACWY-CRM (at 2 and 4 months) as a primary course of vaccination and third dose (at 12 months) as a booster. Infants also received routine vaccines - 3 doses of DTaP-Hib-IPV (at 2, 3, and 4 months), 3 doses of PCV (at 2, 4, and 12 months), and 1 dose each of MMR and Hib (booster) at 13 months of age.~This group had an additional blood draw at 6-7 days after third dose of MenACWY-CRM.

Based on this trial design, predict the completion outcome and termination type (if applicable).